4-Methyl-2-[(2-phenylethyl)amino]-1,3-thiazole-5-carboxylic acid | 196797-64-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Methyl-2-[(2-phenylethyl)amino]-1,3-thiazole-5-carboxylic acid
• 英文别名: 4-methyl-2-(2-phenylethylamino)-1,3-thiazole-5-carboxylic acid
• CAS: 196797-64-5
• 化学式: C₁₃H₁₄N₂O₂S
• mdl: MFCD06655311
• 分子量: 262.33
• InChiKey: ZQAAQDNDAUTZRE-UHFFFAOYSA-N

物化性质

• 沸点：
  467.6±47.0 °C(Predicted)
• 密度：
  1.327±0.06 g/cm3(Predicted)
• 溶解度：
  38.7 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  90.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS
  申请人：Polisetti Dharma Rao

  公开号：US20120029029A1

  公开（公告）日：2012-02-02

  The present invention is directed to substituted thiazol-2-ylamine derivatives and pharmaceutically acceptable salts thereof that inhibit 11βHSD1 and that may be useful in the treatment of diseases in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable.

  本发明涉及取代噻唑-2-基胺衍生物及其药学上可接受的盐，其抑制11βHSD1并可能有助于治疗调节或抑制11βHSD1有益或需要降低细胞内糖皮质激素水平的疾病。本发明还涉及包含这些化合物的制药组合物以及在治疗调节或抑制11βHSD1有益或需要降低细胞内糖皮质激素水平的疾病、疾病或病况中使用这些化合物和组合物的用途。
• US8513430B2
  申请人：——

  公开号：US8513430B2

  公开（公告）日：2013-08-20
• [EN] SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS<br/>[FR] DÉRIVÉS DE THIAZOL-2-YLAMINE SUBSTITUÉS, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION EN TANT QUE MODULATEURS DE 11-BÊTA-HSD1
  申请人：HIGH POINT PHARMACEUTICALS LLC

  公开号：WO2012015715A1

  公开（公告）日：2012-02-02

  The present invention is directed to substituted thiazol-2-ylamine derivatives and pharmaceutically acceptable salts thereof that inhibit 11βHSD1 and that may be useful in the treatment of diseases in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable.